New combo aims to shrink lung tumors before surgery
NCT ID NCT07398937
First seen Feb 15, 2026 · Last updated Apr 25, 2026 · Updated 6 times
Summary
This study tests whether a new drug (serplulimab) combined with chemotherapy works better than another drug (nivolumab) combined with chemotherapy before surgery for stage II to IIIa squamous non-small cell lung cancer. About 116 adults aged 18 to 75 who can tolerate surgery will take part. The main goal is to see if the tumor disappears completely after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-IIIA SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.